REG-Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Genmab announced worldwide DARZALEX net trade sales of $4,239 million for Q3 2026, as reported by license partner Johnson & Johnson. U.S. sales were $2,528 million with the rest of the world at $1,711 million, including the subcutaneous DARZALEX FASPRO product.
Key figures
- Us net sales usd
- 2528000000
- Row net sales usd
- 1711000000
- Darzalex q3 net sales usd
- 4239000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.